Shubham Pant, MD
Enriched profileProfessor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine · The University of Texas MD Anderson Cancer Center
Shubham Pant is Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 619 publications with 10,966 citations (h-index 49); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Shubham Pant, MD, is Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. The public record shows 619 publications with 10,966 citations (h-index 49), centered on Lung Cancer (NSCLC/SCLC), Bladder / Urothelial Cancer, Kidney Cancer / RCC. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 16 companies, 1 NIH-funded awards (2020–2023).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Sponsor: Verastem, Inc.
- A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.
Sponsor: M.D. Anderson Cancer Center
- Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 14 Oct 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202515 payments$25,761openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202519 payments$17,265openpaymentsdata.cms.gov ↗
- Ipsen Biopharmaceuticals, IncProgram year20257 payments$11,398openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.4%Serotonin-3 Receptor Antagonist56.4%Ondansetron Hcl100%Part D≥26 patientsNervous system
43.6%Phenothiazine43.6%Prochlorperazine Maleate100%Part D≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2020–2023 per NIH RePORTER. The latest:
- Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic Cancer
University of Tx Md Anderson Can Ctr
FY2023$392,596P50CA221707 - Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic Cancer
University of Tx Md Anderson Can Ctr
FY2022$391,697P50CA221707 - Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic Cancer
University of Tx Md Anderson Can Ctr
FY2021$248,429P50CA221707
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications.
Clinical cancer research
Article2026 - ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.
JCO precision oncology
Article2026 - BI 905711, a TRAILR2/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings.
Cancer research communications
Clinical Trial2026 - HER2 Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-institutional Analysis.
Clinical cancer research
Article2026
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/shubham-pant-b74008220
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/DrShubhamPant
- X / Twitter
x.com/drspant
Mentions by others
where others cite or feature them- Other
onclive.com/authors/shubham-pant-md-the-university-of-texas-md-anderson-cancer-center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
mdanderson.org/cancerwise/3-recent-advances-in-pancreatic-cancer-research.h00-159780390.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Section Editor
Handbook of Targeted Therapy and Immunotherapy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- APEX Award for Professional Excellence
MD Anderson Center for Professionalism Support and Success
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Director of Clinical Research
Sheikh Zayed Center for Pancreatic Cancer Research, MD Anderson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Professor
Investigational Cancer Therapeutics (Phase I Center), MD Anderson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Clinical Site Director
Partner Network, Ochsner MD Anderson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviews
press, podcasts and appearances- Featured guest
Targeted Oncology video series on KRAS inhibitor daraxonrasib and pancreatic cancer treatment progress
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →amazon.com ↗
- Contributor
Huffington Post India (personal writing)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - Guest
BackTable Tumor Board Podcast, discussing systemic therapy for advanced pancreatic cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →backtable.com ↗ - Recurring video/podcast contributor at OncLive on pancreatic cancer
FGFR-altered solid tumors, and targeted therapy
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center